Javascript must be enabled to continue!
Potentiation of the depressor effect of acetylcholine by carvedilol
View through CrossRef
Carvedilol, a beta‐1,2 and alpha‐1 adrenoceptor blocker was explored in anesthetized rats in which systolic pressure was measured to determine if it enhances the vasodilator effect of single doses of acetylcholine (0.1, 0.15, 0.2, 0.25, 0.5 ug) by enhancing the availability of nitric oxide. At a maximal cumulative dose(1.364±0.228mg/kg) carvedilol potentiated the depressor effect of acetylcholine by 32‐15% (lowest to highest dose, P<0.01‐0.001). This effect was annulled by prevention of nitric oxide synthesis with nitro‐L‐arginine (15mg/kg) and restoration of the baseline systolic pressure with an infusion of nitroglycerin, a nitric oxide donor. Giving this treatment before carvedilol also prevented its potentiation of acetylcholine effect. Carvedilol may partly enhance the depressor effect of acetylcholine by annulling the reflexly‐mediated sympathetic compensation for the hypotension through its alpha‐1 adrenoceptor blockade. Pretreatment with phenoxybenzamine, a blocker of alpha‐1,2 adrenoceptors and an infusion of angiotensin II to restore basal systolic pressure to baseline had minimal effect on the depressor action of acetylcholine. This was also true with pretreatment with propranolol. It is concluded that carvedilol potentiated the depressor effect of acetylcholine essentially by enhancing the synthesis of nitric oxide. Supported by the American University of Beirut.
Title: Potentiation of the depressor effect of acetylcholine by carvedilol
Description:
Carvedilol, a beta‐1,2 and alpha‐1 adrenoceptor blocker was explored in anesthetized rats in which systolic pressure was measured to determine if it enhances the vasodilator effect of single doses of acetylcholine (0.
1, 0.
15, 0.
2, 0.
25, 0.
5 ug) by enhancing the availability of nitric oxide.
At a maximal cumulative dose(1.
364±0.
228mg/kg) carvedilol potentiated the depressor effect of acetylcholine by 32‐15% (lowest to highest dose, P<0.
01‐0.
001).
This effect was annulled by prevention of nitric oxide synthesis with nitro‐L‐arginine (15mg/kg) and restoration of the baseline systolic pressure with an infusion of nitroglycerin, a nitric oxide donor.
Giving this treatment before carvedilol also prevented its potentiation of acetylcholine effect.
Carvedilol may partly enhance the depressor effect of acetylcholine by annulling the reflexly‐mediated sympathetic compensation for the hypotension through its alpha‐1 adrenoceptor blockade.
Pretreatment with phenoxybenzamine, a blocker of alpha‐1,2 adrenoceptors and an infusion of angiotensin II to restore basal systolic pressure to baseline had minimal effect on the depressor action of acetylcholine.
This was also true with pretreatment with propranolol.
It is concluded that carvedilol potentiated the depressor effect of acetylcholine essentially by enhancing the synthesis of nitric oxide.
Supported by the American University of Beirut.
Related Results
Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Abstract
Objective: To investigate the protective effect of carvedilol against atherosclerosis by inhibiting the NLRP3 inflammasome.
Methods:In vitro experiments, human umb...
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
1. The alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol, a beta‐adrenoceptor antagonist with vasodilating properties, and labetalol were investigated in 10 healthy ma...
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
AbstractThis study evaluates the carvedilol‐lercanidipine drug interaction, and the influence of chronic kidney disease (CKD) on both drugs. Patients with high blood pressure (8 wi...
Clinical study evaluating the gastroprotective effect of carvedilol in patients with ischemic heart disease on aspirin therapy
Clinical study evaluating the gastroprotective effect of carvedilol in patients with ischemic heart disease on aspirin therapy
Abstract
Background and purpose
Despite its therapeutic benefits in ischemic heart disease (IHD) patients, using aspirin represents a significant...
Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Objective
To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF).
...
Both Carvedilol and Nebivolol May Improve Platelet Function and Prothrombotic State in Patients With Nonischemic Heart Failure
Both Carvedilol and Nebivolol May Improve Platelet Function and Prothrombotic State in Patients With Nonischemic Heart Failure
It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF). Thus, we compared their effects on...
Carvedilol Produces Sustained Long‐Term Benefits: Follow‐Up at 12 Years
Carvedilol Produces Sustained Long‐Term Benefits: Follow‐Up at 12 Years
The authors measured long‐term outcomes of patients who initiated carvedilol between 1990 and 1992 to test the hypothesis that carvedilol produces sustained benefits in heart failu...
Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia
Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia
Background:
Iron overload cardiomyopathy is the most common cause of death in patients with transfusion-dependent thalassemia.
Aim:
...

